Engineered immune cells take on recurrent brain tumors in early trial
NCT ID NCT02208362
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This early-stage study tests a new treatment for people with malignant glioma that has returned or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), add a special gene to help them recognize and attack the tumor, and infuse them back. The main goals are to find the safest dose and understand side effects. The study involves 65 participants and is currently active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.